CN114174336B - 针对人和犬ctla-4的犬源化抗体 - Google Patents

针对人和犬ctla-4的犬源化抗体 Download PDF

Info

Publication number
CN114174336B
CN114174336B CN202080050832.8A CN202080050832A CN114174336B CN 114174336 B CN114174336 B CN 114174336B CN 202080050832 A CN202080050832 A CN 202080050832A CN 114174336 B CN114174336 B CN 114174336B
Authority
CN
China
Prior art keywords
seq
canine
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080050832.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114174336A (zh
Inventor
M·莫尔塞耶
张远征
I·塔佩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Priority to CN202411315030.1A priority Critical patent/CN119307505A/zh
Publication of CN114174336A publication Critical patent/CN114174336A/zh
Application granted granted Critical
Publication of CN114174336B publication Critical patent/CN114174336B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080050832.8A 2019-07-15 2020-07-15 针对人和犬ctla-4的犬源化抗体 Active CN114174336B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411315030.1A CN119307505A (zh) 2019-07-15 2020-07-15 针对人和犬ctla-4的犬源化抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874287P 2019-07-15 2019-07-15
US62/874,287 2019-07-15
PCT/EP2020/069924 WO2021009188A1 (en) 2019-07-15 2020-07-15 Caninized antibodies to human and canine ctla-4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411315030.1A Division CN119307505A (zh) 2019-07-15 2020-07-15 针对人和犬ctla-4的犬源化抗体

Publications (2)

Publication Number Publication Date
CN114174336A CN114174336A (zh) 2022-03-11
CN114174336B true CN114174336B (zh) 2024-10-11

Family

ID=71620455

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080050832.8A Active CN114174336B (zh) 2019-07-15 2020-07-15 针对人和犬ctla-4的犬源化抗体
CN202411315030.1A Pending CN119307505A (zh) 2019-07-15 2020-07-15 针对人和犬ctla-4的犬源化抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411315030.1A Pending CN119307505A (zh) 2019-07-15 2020-07-15 针对人和犬ctla-4的犬源化抗体

Country Status (8)

Country Link
US (1) US20220251209A1 (enExample)
EP (1) EP3999539A1 (enExample)
JP (2) JP7695228B2 (enExample)
CN (2) CN114174336B (enExample)
AU (1) AU2020312687A1 (enExample)
BR (1) BR112022000604A2 (enExample)
CA (1) CA3145347A1 (enExample)
WO (1) WO2021009188A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022000604A2 (pt) * 2019-07-15 2022-03-03 Intervet Int Bv Anticorpos caninizados para ctla-4 humana
WO2024145278A2 (en) 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
WO2024155982A2 (en) 2023-01-20 2024-07-25 Invetx, Inc. Bispecific binding agents for use in companion animals
CN117343185B (zh) * 2023-12-06 2024-03-01 北京伟杰信生物科技有限公司 一种抗犬pd-1抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547595A (zh) * 2011-03-09 2014-01-29 安迪拓普有限公司 人源化ctla-4抗体

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
CA2356215C (en) 1998-12-23 2015-11-24 Pfizer Inc. Human monoclonal antibodies to ctla-4
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2001253282A1 (en) * 2000-04-07 2001-10-23 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2003060080A2 (en) * 2001-12-21 2003-07-24 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
CA2754408A1 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
HK1201281A1 (en) * 2011-10-13 2015-08-28 Nexvet Australia Pty Ltd Canine/feline cd20 binding epitope and compositions for binding thereto
JP6629069B2 (ja) * 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
BR112016014284A2 (pt) * 2013-12-20 2017-12-05 Intervet Int Bv anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
US10550194B2 (en) 2014-09-30 2020-02-04 Intervet Inc. PD-L1 antibodies binding canine PD-L1
CN113861294B (zh) * 2015-04-02 2024-03-08 英特维特国际股份有限公司 针对犬白介素-4受体α的抗体
WO2017062615A2 (en) * 2015-10-08 2017-04-13 Macrogenics, Inc. Combination therapy for the treatment of cancer
PT3390451T (pt) * 2015-12-18 2025-03-12 Intervet Int Bv Anticorpos humanos caninizados para il-4r alfa humano e canino
AU2017315146A1 (en) * 2016-08-26 2019-04-11 Sanofi Multispecific antibodies facilitating selective light chain pairing
BR112021004723A2 (pt) * 2018-09-14 2021-06-08 Kindred Biosciences, Inc. anticorpos de receptor anti-il4 para uso veterinário
BR112022000604A2 (pt) * 2019-07-15 2022-03-03 Intervet Int Bv Anticorpos caninizados para ctla-4 humana

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547595A (zh) * 2011-03-09 2014-01-29 安迪拓普有限公司 人源化ctla-4抗体

Also Published As

Publication number Publication date
JP7695228B2 (ja) 2025-06-18
BR112022000604A2 (pt) 2022-03-03
CN114174336A (zh) 2022-03-11
EP3999539A1 (en) 2022-05-25
CA3145347A1 (en) 2021-01-21
AU2020312687A1 (en) 2022-01-27
JP2025081549A (ja) 2025-05-27
US20220251209A1 (en) 2022-08-11
JP2022541767A (ja) 2022-09-27
CN119307505A (zh) 2025-01-14
WO2021009188A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
US10927172B2 (en) Caninized murine antibodies to human PD-1
CN114174336B (zh) 针对人和犬ctla-4的犬源化抗体
JP2019506146A (ja) ヒトおよびイヌｉｌ−４ｒアルファに対するイヌ化ヒト抗体
JP2025159730A (ja) イヌｃｔｌａ－４に対するイヌ化抗体
RU2822460C2 (ru) Канинизированные антитела против человеческого ctla-4
RU2818586C2 (ru) Антитела против собачьего ctla-4

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant